Key figures (Sep 2011 - Oct 2022)
Some former students' testimonials
I enjoyed every moment of the master's program
The Eu2P Master's program was a rewarding experience
The knowledge gained has changed my professional career and business perspectives, assisting multiple international organizations in introducing and performing clinical trials and evidence-based clinical procedures in developing markets
I was also able to find employment very soon after completing the Master thanks to my new PV skills
One of the most rewarding decisions I made for my career
The courses offered reflect the actual practice in the work environment.
Organisations trusting us for staff competency development
- Real-life practices inputs from insiders such as the regulatory and industry members of the Eu2P consortium and from international guest experts invited to share experience and interact with students
- Course compliance with the core competencies and knowledge requirements such as WHO-ISoP requirements for pharmacovigilance and ISPE requirements for pharmacoepidemiology and with the imi-train competency profiles in Drug Safety Sciences
- Inclusion of last research and methodologies advances in collaboration with the IMI PROTECT stakeholders
- The full online courses approach to ease professional study-time management has been awarded a trophy for higher education innovation (Educatec-Educatice 2012)
- Modular and time flexible courses comply with lifelong learning and continuing professional development as described by the LifeTrain initiative
- Academic standards and quality of the programme are ensured by the Eu2P Executive Board including academic representatives of the 6 Eu2P degree awarding universities
- Compliance with main quality items of ENQA's report on "Standards and Guidelines for Quality Assurance in the European Higher Education Area"
- Cross quality review of assessments between Eu2P academic partners
- Independent external examination of programme assessments and equity
Recommendations & collaborations
Eu2P training programme is recommended by the ENCePP
as important in building future capacity in the European Union to undertake high quality, scientifically independent research.
The North America chapter from the International Society of Pharmacovigilance (NASoP) has collaborated with Eu2P to build a new education program tailored to North American medicines-stakeholders, the American Program in Pharmacovigilance Am2P.
IMI PROTECT project and Eu2P fostered collaboration in postgraduate training and exchange of trainees between pharmacovigilance and pharmacoepidemiology centres. PROTECT has also provided pharmacoepidemiological research findings and new methodology inputs for Eu2P teaching materials and programmes.
Eu2P training programme has been awarded a PharmaTrain Centre Recognition following a quality assessment of its Master Education and Training programme by The PharmaTrain Federation.
IMI EMTRAIN's On-course®, the European portal of biomedical postgraduate education and training resources has indexed Eu2P courses and provides a Eu2P course filter in its Advanced Search feature.
IMI SafeSciMET has collaborated with Eu2P to adapt course modules into a blended learning format on the Eu2P eLearning platform under the collaborative framework of the imi-train project.
IMI European platform for education and training in the medical, biomedical and pharmaceutical sciences, imi-train, promotes Eu2P academic postgraduate programmes as well as CPD training in pharmacovigilance and pharmacoepidemiology.
Publications & media highlights
- European Regulatory Science and Regulatory Science Expert Training Project .
Shin et al.
Korean Journal of Clinical Pharmacy (2021).
- A Multidisciplinary Approach in Pharmacovigilance Awareness: ISoP Egypt Chapter's MedSafetyWeek Experience.
Rostom et al.
Drug Safety (2021).
- A systematic review on learning outcomes of pharmacovigilance issues: Undergraduates of pharmacy.
International Journal of Educational Research (2021).
- Global Pharmacovigilance, challenges, and future considerations: West globe and East globe.
Gadhade JS, Hiray RS.
Journal of Pharmacovigilance and Drug Research (2021).
- Drug safety academic programme expands to North America.
Innovative Medicines Initiative (2021).
- For research projects to leave a legacy, long-term vision is vital.
Innovative Medicines Initiative (2021).
- An Update of the North American Chapter of the International Society of Pharmacovigilance (NASoP).
Gossell-Williams, M. et al.
Drug Safety (2021).
- Socio-Economic Impact Report on IMI1 projects.
Centre for Innovation in Regulatory Science (2021).
- Chapter 23 - Translational safety medicine.
Ernst et al.
Principles of Translational Science in Medicine (Third Edition 2021).
- Harmonizing and improving European education in prescribing: An overview of digital educational resources used in clinical pharmacology and therapeutics.
M. J. Bakkum et al.
British Journal of Clinical Pharmacology (2020).
- Pharmacovigilance: Challenges in Getting From Here to There.
Clinical Therapeutics (Dec. 2018).
- Pharmacovigilance: Our experience in Aden.
M. Alshakka and W. Badulla
World Journal of Pharmaceutical Sciences (Oct. 2018).
- A Review of the Contributions of Cross-discipline Collaborative European IMI/EFPIA Research Projects to the Development of Replacement, Reduction and Refinement Strategies.
Alternatives to Laboratory Animals (May 2018).
- Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action.
A. Radecka, L. Loughlin, M. Foy, M. Viana de Ferraz Guimaraes, V. Macolic Sarinic, M. Dimov Di Giusti, M. Lesicar, S. Straus, D. Montero, J. Pallos, J. Ivanovic, J. Raine
Drug Saf (2018).
- What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects.
R. van Eekeren, L. Rolfes, A.S. Koster, L. Magro, G. Parthasarathi, H. Al Ramimmy, T. Schutte, D. Tanaka, E. van Puijenbroek, L. Härmark
Drug Saf (2018).
- 'All this wouldn’t have been possible without IMI' - an interview with Eu2P project coordinators.
IMI JU in Success stories from projects, 01 February 2018.
- Carrying the torch for medical innovation.
IMI JU in IMI Results and Impact, 06 Octobre 2017.
- Risk Communication in a Pharmacovigilance Environment.
Clinical Therapeutics. 39, no. 4 (April 2017): 672–74.
- An Introduction to Pharmacovigilance, 2nd Edition.
P. Waller, and M. Harrison-Woolrych
Wiley-Blackwell, April 2017.
- Practical Implementation in Six Member States.
M. Kaeding, J. Schmälter, C. Klika. in Pharmacovigilance in the European Union : Practical Implementation across Member States, edited by Wiesbaden: Springer, February 2017.
- البرنامج الأوروبي في اليقظة الدوائية: درجة الماجستير في اليقظة الدوائية عن بعد [European programme in pharmacovigilance: distant pharmacovigilance Master programme]
هاجر علي [Hager Ali]
Egypt Scholars blog May, 2017
- From Face-to-Face training to blended learning in the postgraduate program SafeSciMET - a case study.
J.C. Vos, S. Dragovic, M. Jochimsen, J. Dirach, H. Foth, J. Wiese, O.J. Bjerrum
Eur. J. Pharm. Sci., 01 January 2017.
- Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data.
O. Yildirim, M. Gottwald, P. Schüler and M.C. Michel
Front. Pharmacol., 06 December 2016.
- Job and Career Opportunities in the Pharmaceutical Sector.
J.R. Thomas, C. van Schravendijk, L. Smit and L. Saso.
In Special Topics in Drug Discovery, edited by T. Chen and S.C. Chai, November 2016.
- Elaboration et évaluation d’un site d’e-learning pour l’apprentissage de la recherche en médecine générale.
N. De Chanaud.
Thèse de Médecine Générale, 27 septembre 2016.
- How can an adaptive training programme support change in organisational strategy?
Intrinsic Activity, 2016; 4 (Suppl. 1): A4.1
- Essential learnings: How do I begin...?
benefit-risk assessment, the blog around structured decision making in medicine, June, 2016
- Shaping Europe's Vision for Personalised Medicine.
The PerMed SRIA (Strategic Research and Innovation Agenda), Jul. 2015.
- Structured Benefit–risk Assessment: A Review of Key Publications and Initiatives on Frameworks and Methodologies.
S. Mt-Isa, M. Ouwens, V. Robert, M. Gebel, A. Schacht, and I. Hirsch.
Pharmaceutical Statistics, May 2015.
- European Initiatives for Better Training in Medicines Development.
Journal of Medicines Development Sciences 1, no. 1 (May 2015).
- Guide de Conception de Formation Ouverte et à Distance (FOAD) Dans Le Monde de La Santé.
Haute Autorité de santé, Apr. 2015.
- The Innovative Medicines Initiative: an engine for regulatory science.
M. Goldman, N. Seigneuret, H.G. Eichler
Nat Rev Drug Discov. 2015 Jan;14(1):1-2.
- Chapter 6 - How Can the Innovative Medicines Initiative Help to Make Medicines Development More Efficient?
In Re-Engineering Clinical Trials, 55–63. Elsevier - Academic Press, Jan. 2015.
- Teaching Pharmacovigilance: The WHO-ISoP Core Elements of a Comprehensive Modular Curriculum.
J. Beckmann, U. Hagemann, P. Bahri, A. Bate, I.W. Boyd, G.J. Dal Pan, B.D. Edwards, et al.
Drug Safety, Aug. 2014, 1–17.
- Practical Experience in Teaching Pharmacovigilance.
S. Evans, and I. Douglas
In Mann's Pharmacovigilance, 805–6. John Wiley & Sons, Ltd, Apr. 2014.
- Eu2P: The First European Online Public–Private Joint Training Program in Pharmacovigilance and Pharmacoepidemiology.
K. Palin, C. Bataille, S. Liège, R. Schimmer, and A. Fourrier-Réglat
In Mann's Pharmacovigilance, 785–92. John Wiley & Sons, Ltd, Apr. 2014.
- Bordeaux : L'Université Se Met Au Numérique.
France 3 Aquitaine. Feb. 2014.
- Towards a Single VOICE for European Clinical Pharmacology: Proposals for Future Developments.
J.K. Aronson and G. Velo.
European Journal of Clinical Pharmacology 69, no. 11 (Nov. 2013): 1981–84.
- La Formation à Distance 'Made in Aquitaine' Qui Intéresse Harvard.
Journal l'Aquitaine, journal d'information du Conseil Régional d'Aquitaine, Sep. 2013.
- Prescrire juste, plutôt que juste prescrire.
M. Molimard, M.-C. Perault-Pochat, C. Funck-Brentano, M. Bardou, R. Bordet, and J.-L. Montastruc.
Le Monde.fr, Apr. 2013.
- Regulatory Science: Researchers in the Pipeline.
Nature 496, no. 7445 (Apr. 2013): 387–89.
- Opening Industry-Academic Partnerships.
Science, Apr. 2013.
- Background Paper 7.4 Pharmacogenetics and Stratified Medicine.
S.J.H. Vijverberg, A.-H. Maitland-van der Zee.
From Priority Medicines for Europe and the World Project "A Public Health Approach to Innovation" by the World Health Organization, Mar. 2013.
- Enseignement : Bordeaux Segalen Tient La Distance.
Sud-Ouest Feb. 2013.
- Continuing Medical Education and Professional Development in the European Union.
H. Silva, F.R. Bühler, B. Maillet, H. Maisonneuve, L.A. Miller, A. Negri, and P.D. Stonier.
Pharmaceutical Medicine 26, no. 4 (Dec. 2012): 223–33.
- Better Comms in Meds.
K. Palin, C. Bataille, S. Liège, E. Swain, A. Fourrier-Réglat, and R. Schimmer.
Public Service Review: Health and Social Care, no. 34 (Dec. 2012): 71.
- TV report on Eu2P programme
Emission Modes d'Emplois.
TV7 Bordeaux, Nov. 2012.
- Pharmacovigilance Medical Writing: A Good Practice Guide
Wiley-Blackwell, July 2012
- Conference Scene: 5th Anniversary Meeting of the European Research Network Pharmacogenetics/Pharmacogenomics.
J.C. Fox, A. Daly, I. Cascorbi, A. Alfirevic, H. Linden, and A.-H. Maitland-van der Zee
Pharmacogenomics Vol. 13, No. 7 (May 2012): 747-749.
- European Initiative towards Quality Standards in Education and Training for Discovery, Development and Use of Medicines.
H. Klech, C. Brooksbank, S. Price, P. Verpillat, F.R. Bühler, D. Dubois, N. Haider, et al.
European Journal of Pharmaceutical Sciences 45, no. 5 (Apr. 2012): 515–20.
- The Innovative Medicines Initiative: A European Response to the Innovation Challenge.
Clinical Pharmacology & Therapeutics 91, no. 3 (Mar. 2012): 418–25.
- Cobert's Manual of Drug Safety and Pharmacovigilance.
Jones & Bartlett Learning 2011.
I enjoyed every moment of the master's program. The subjects are broad and comprehensive yet delivered in a manner that is easy to digest and progress through at a reasonable pace. Karine, Christa and Stephane were always responsive and helpful, regardless of the request or assistance that was required.
The Eu2P Master's program was a rewarding experience. It was challenging and I also met wonderful people from all over the world. The professors made themselves available and ensure you reach out to them. Be disciplined with your school schedule and you will succeed!
I highly recommend the Eu2P masters programme; all components are very well integrated and updated to current standards and practices. The possibility to have access and interact continuously with experienced professors and renowned professionals working in the pharmaceutical industry is a plus. The knowledge gained has changed my professional career and business perspectives, assisting multiple international organizations in introducing and performing clinical trials and evidence-based clinical procedures in developing markets.
Enrolling in the Eu2P Master was the beginning of a career change for me. The program was intellectually challenging and I appreciated the themed modules. The online courses made it possible to sustain a good work/life balance. I also appreciated the diversity of trainees from all over the world; it was fascinating to have this global perspective. Many of the modules were taught not only by academics, but by PV industry professionals who brought real-world perspectives and experience. Finishing the program was extremely rewarding not only at the personal level, but I was also able to find employment very soon after completing the Master thanks to my new PV skills. I would highly recommend the program to anyone who wants to develop their PV skills.
The Eu2P Master's programme was one of the most rewarding decisions I made for my career. The instruction provided by the combination of academics and industry experts was invaluable. The calibre of students enrolled and their diversity allows for different perspectives to be shared in the learning platform. I also appreciated the choice in the modules in Master year 2 which could be tailored according to your preference towards pharmacoepidemiology or pharmacovigilance. I would definitely recommend this programme to any professional that is serious about a career in pharmacovigilance and pharmacoepidemiology.
What a great and exciting journey! I highly recommend Eu2P to people who are interested in the career of Pharmacovigilance and Pharmacoepidemiology. It is created and presented by highly qualified team from both the academic and professional sectors. The courses offered reflect the actual practice in the work environment. Personally, it helped me a lot in my work, increased my knowledge and improved my way of thinking when dealing with pharmacovigilance related queries and challenges. Having the master program as a part time was an optimum choice to be able to complete it while I am working. The flexibility, understanding and collaboration of Eu2P office and academic team decreased a lot of burdens and obstacles faced because of studying and working at the same time.